share_log

EF Hutton Initiates Coverage On Atara Biotherapeutics With Buy Rating, Announces Price Target of $25

EF Hutton Initiates Coverage On Atara Biotherapeutics With Buy Rating, Announces Price Target of $25

EF Hutton以买入评级启动对Atara生物疗法的报道,宣布目标价为25美元
Benzinga Real-time News ·  2023/01/05 04:45

EF Hutton analyst Tony Butler initiates coverage on Atara Biotherapeutics (NASDAQ:ATRA) with a Buy rating and announces Price Target of $25.

EF Hutton分析师Tony·巴特勒对雅达拉生物疗法公司(纳斯达克:ATRA)的报道给予买入评级,并宣布目标价为25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发